Condition
Phase II
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Not Yet Recruiting2
Recruiting1
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07438626Phase 2RecruitingPrimary
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
NCT07720115Phase 2WithdrawnPrimary
Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
NCT07753824Phase 2Not Yet RecruitingPrimary
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
NCT07549451Phase 2Not Yet RecruitingPrimary
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
Showing all 4 trials